The Future of 3D Printing in Pharma

Get this report now

3D Printing: Move beyond the hype and discover its true commercial value

3D printing has the potential to impact the entire product lifecycle. No longer just the darling of R&D departments, this fledgling technology is extending its reach. Although experts agree it’s not a panacea, it certainly can’t be ignored either. What difference is 3D printing making now? What developments are expected? And what is the single biggest factor that could seriously hamper further progress if pharma doesn’t lay the right foundations today?

Report Overview

The Future of 3D Printing in Pharma cuts through the hype and identifies where the tangible value can be gained from this emerging technology. Insights are drawn from interviews with 8 experts from pharmaceutical and technology companies and institutes at the forefront of these ground-breaking new developments.

Report Features

• Summary of the lessons already learned, both from within pharma circles and in other sectors further ahead in the development and application phases.
• Assessment of the set-up and resources to consider, including the various disciplines, external alliances, and the impact on current structures.
• Detailed discussion on potential commercial opportunities and how these can be aligned with clinical need.
• Pragmatic view of the transition from academic development to business innovation and the risks involved.

Key Benefits

• Separates the facts from the hype: Gain clarity on developments to date as well as the wider ramifications of adopting this new technology including cost, scalability and time to market.
• Puts 3D printing into the context of pharma: Understand possible applications as well as where the most potential lies to benefit drug developers, manufacturers, payers and patients.
• Provides thought provoking ideas and inspiration: Find out what the experts are saying about what the future holds, not just for the pharma industry but for the wider medical community.
• Brings decision-makers up-to-speed: Use this report to kick-start internal discussions across your organisation on where 3D printing fits and the opportunities to be accommodated.

Report available for immediate download -- place your order today

Why 3D printing matters for pharma

Clearly there is little point in innovation for its own sake. 3D printing has been of interest in pharma R&D departments for a while, but now others are also taking notice – and for good reason. 3D printing may well be the catalyst that transforms the drug manufacturing landscape forever, not only in terms of how drugs are manufactured and administered but also in key areas such as speed to market, cost and personalisation. As the technology is now so accessible, the question for pharma companies is not ‘should you be involved?’, it’s ‘why wouldn’t you?’

Key Questions Answered By This Report

• Who has a role to play? Is patient focus a departmental or company-wide strategy? Is it just about patients or should pharma also engage with family members, carers and others?
• What are the commercial benefits? Are there key metrics to have in place to keep track of progress? What does success look like?
• How is the concept of patient centricity similar to ethics within pharma? What can be learned from reviewing how an ethical stance is accepted and embedded across the business?
• When does the patient become most important? At what point in the product lifecycle should pharma seek to engage patients? How should engagement take place?

Key Questions Answered By This Report

• Where does 3D printing belong? Is it just in R&D and prototyping or are there real opportunities in manufacturing? Ultimately, how likely is decentralisation of manufacturing in the long term?
• Is it time to open the floodgates for personalisation of medicine? Can 3D printing successfully create customised pills or devices that more closely meet patient needs?
• Is the technology a match for pharma quality standards? Risk of abuse and counterfeiting are not new issues, but does 3D printing present any further complications in these key areas?
• How could the widespread adoption of 3D printing transform the supply chain and bring the end product closer to the patient? Will pharma companies become designers and developers only?
• What is the value proposition? And what are the opportunities, risks and challenges associated with the potential gains?

Find answers to these and many more important questions — download the report today

Expert Views

• Dr Mohammed Albed Alhnan, Lecturer in Pharmaceutics, School of Pharmacy and Biomedical Sciences, University of Central Lancashire, UK
• Adam Cohen, Principal Consultant and CEO, Additive Insight LLC, USA
• Stephen Hilton, Senior Lecturer, Department of Pharmaceutical and Biological Chemistry, UCL School of Pharmacy, UK
• John F. Hornick is an intellectual property (IP) counsellor and litigator based in Finnegan’s Washington DC headquarters
• Dr Jason Jones, Founder & CEO of Hybrid Manufacturing Technologies, USA
• Christopher D. Lunsford, MD, Assistant Professor, General Physical Medicine and Rehabilitation, University of Virginia
• Clive Roberts, Chair of Pharmaceutical Nanotechnology, Head of School, Faculty of Science, University of Nottingham, UK
• Martin Wallace, Director of Technology Seeking, GlaxoSmithKline

3 Key Quotes

“What's interesting about 3D printing is the crossover point where it becomes economically as well as technically interesting. The next question is, will it be clinically and commercially successful? Of course, that's not a given with any product.”
Clive Roberts, University of Nottingham, UK

Critical insights from these and many other respected experts available for immediate download —place your order here

Who Would Benefit from This Report?

• Senior leadership and long term strategy planners
• R&D managers involved in drug development, device design, innovative technologies
• Trial designers looking for quick and effective new methods to produce drugs on batch
• Market access managers considering product positioning, new markets, logistics and supply chain
• Procurement, insurers and payers anticipating changing cost models
• Pharmacists and PBMs seeking insight into the shape of future markets

Report available for immediate download — place your order here

Content Highlights

• Setting the scene
• What is 3D printing?
  • 3D printing technologies
  • 3D printing companies
• Why should pharma invest in 3D printing technology?
  • Key findings
  • Drug manufacturing
  • Rapid prototyping
  • Improve chemical synthesis
  • Limited capital investment improves time savings
  • Scalability, flexibility and reproducibility
  • Pharma R&D
  • Bioprinting for medical research and therapeutics
  • Personalisation of medicine
• What’s the value proposition of 3D printing?
  • Key findings
  • Education and Economic viability
  • De-risk the development process
  • Provide the investor with a competitive edge
  • Early adoption in clinical formulations
  • Risk of abuse and counterfeiting
  • Academic innovation
  • Pharma involvement
  • National 3D printing strategies
• Regulation and the IP landscape
  • Key findings
  • US regulation
  • EU regulation
  • Safeguarding future investment
  • Patent activity
  • Leading bioprinting patent holders
  • Pharma activity
  • The future: Looking beyond the hype
  • Technological revolution
  • Improve market access
  • Patient-centric healthcare
  • Point of care delivery
• Take-home messages
  • Clinical need will be the driver
  • Supply chain economics
  • Speed of innovation

Get this report now